Over 320 Million Opioid Pills Sent from India to West Africa in Three Years, Investigation Reveals

Indian pharmaceutical companies have exported more than 320 million tapentadol pills to West Africa over the past three years, a quantity that dwarfs any previous estimate of the region's synthetic opioid crisis, according to an investigative report published by Bellingcat in April 2026. Tapentadol — a potent synthetic opioid that is two to three times stronger than morphine — is classified as a controlled substance in most countries but has been manufactured and exported legally from India under licenses that do not require recipients to hold pharmaceutical import licenses in many West African nations.

The investigation, which analyzed trade data, shipping records, and customs documentation, found that over 1,400 shipments of tapentadol tablets — often branded and packaged in ways that imply safe over-the-counter use — were dispatched from Indian pharmaceutical facilities to distributors across Nigeria, Ghana, Togo, Benin, and other West African markets between 2023 and 2026. The scale of the trade has overwhelmed drug enforcement agencies in countries that lack the infrastructure to track, interdict, or properly regulate the inflow of controlled substances.

Why Tapentadol? A Drug Designed for Exploitation

Tapentadol was developed as a prescription opioid for severe pain management, and is approved for medical use in the United States, Europe, and many other countries — but notably not in most West African states, where it has never received regulatory clearance from national medicines boards. Despite this, the drug has flooded the region through a legal loophole that allows the export of unscheduled pharmaceutical products from India without requiring importers to demonstrate they hold valid medical import licenses.

The outcome has been catastrophic. Street-level dealers in Lagos, Accra, Lome, and Cotonou report ready availability of tapentadol at relatively low prices, making it accessible to young people, informal workers, and vulnerable populations with limited awareness of the risks. Addiction rates are climbing, and hospital emergency rooms in Nigeria and Ghana are reporting increasing numbers of overdose cases, though data collection remains poor. Public health officials warn that the true scale of the crisis is likely far larger than what official records capture.

Health Systems Under Strain

The arrival of a synthetic opioid at this scale is placing enormous pressure on healthcare systems that are already under-resourced and struggling to cope with the double burden of communicable diseases and chronic conditions. Unlike tramadol, which has been the subject of an earlier wave of flooding into the region, tapentadol carries a significantly higher risk of respiratory depression at high doses — meaning that unsupervised use can quickly become fatal.

Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) has seized large quantities of tapentadol in multiple operations across Lagos, Kano, and Port Harcourt, but enforcement remains patchy and often reactive rather than proactive. In Ghana, the Food and Drugs Authority has only recently begun engaging with international counterparts to trace the supply chains behind the influx. NGOs working on drug policy and harm reduction say they are operating with minimal government support and insufficient funding.

India's Responsibility and International Law

Bellingcat's investigation highlights a critical regulatory gap at the international level: there is currently no mechanism that requires exporting countries to verify that recipient nations have functioning regulatory frameworks for controlled substances before granting export licenses. India, which has a large and legitimate pharmaceutical export industry, has come under increasing pressure to tighten controls on exports of opioids to regions where regulatory oversight is known to be weak.

The African Union and ECOWAS have both passed resolutions calling for greater international cooperation on the diversion of pharmaceutical drugs, but enforcement remains a distant goal. Several advocacy organizations have called on the International Narcotics Control Board (INCB) to take a more active role in monitoring shipments of controlled substances to regions with documented enforcement gaps.

The Road Ahead: Regulation or Continued Flooding?

Without urgent action — both at the regulatory level in importing countries and through diplomatic pressure on Indian pharmaceutical exporters — the tapentadol crisis is likely to deepen. Nigeria, Ghana, and other affected nations are pushing for changes to customs classification to criminalize possession and distribution, but legal reforms move slowly while the trade accelerates. For the millions of young West Africans already exposed to opioid use, the question is not whether the crisis will grow, but how many lives will be lost before the international community treats it as the emergency it plainly is.